Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
An announcement from OncoSil Medical Ltd ( (AU:OSL) ) is now available.
OncoSil Medical Limited has completed a capital consolidation on a 1 for 400 basis, as approved by shareholders, to streamline its capital structure. This move is part of the company’s strategy to enhance its market position as it continues to commercialize its innovative cancer treatment technology. The consolidation is expected to impact trading, with normal trading on a post-consolidation basis set to commence on June 13, 2025.
More about OncoSil Medical Ltd
OncoSil Medical Limited is a company specializing in the development of cancer treatment devices, particularly the OncoSil™ brachytherapy device. This device is a significant component of a novel brachytherapy treatment for locally advanced unresectable pancreatic cancer, a condition with a poor prognosis and high incidence worldwide. The OncoSil™ device, which delivers targeted intratumoural placement of Phosphorous-32, has received breakthrough device designation in the EU, UK, and US, and is approved for sale in over 30 countries.
Average Trading Volume: 24,333
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$10.94M
See more insights into OSL stock on TipRanks’ Stock Analysis page.